---
layout: splash
title: 에스티팜 (237690)
excerpt: 에스티팜의 최근 공시, 수익률, 주요 재무/기술 지표
header:
  overlay_color: "#333"
  show_overlay_excerpt: false
categories:
- KOSDAQ
- Q:제약
- 고PER
keywords: 에스티팜, 237690
---

| **종가** | **전일대비** | **업종** | **PER** | **PBR** | **DIV** |
| -------: | -----------: | -------: | ------: | ------: | ------: |
| 99,500 | <span style="color: cornflowerblue">-0.8<small>%</small></span> | Q:제약 | 95.6 | 4.9 | 0.5<small>%</small> |

<!-- more -->


> **기업 개요**<a id="company"></a>

| <span style="white-space:nowrap;">**섹터**</span> | Q:제약 / 의약품 제조업 |
| <span style="white-space:nowrap;">**산업**</span> | 원료의약품 |
| <span style="white-space:nowrap;">**상장**</span> | KOSDAQ / 2016년 6월 23일 상장 / 12월 결산 |
| <span style="white-space:nowrap;">**대표자**</span> | Sung Moo-je |
| <span style="white-space:nowrap;">**홈페이지**</span> | [http://www.stpharm.co.kr](http://www.stpharm.co.kr){:target="_blank"} |


> **최근 7일 DART 신규 공시**<a id="dart"></a>

| **일자** |      | **보고서명** |
| :------- | :--- | :----------- |
| 09&#x2011;09 | | [투자판단관련주요경영사항(임상시험결과)              (탄키라제 항암제 STP1002의 제1상 임상시험 결과)](https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20240909900069){:target="_blank"} |
| 09&#x2011;05 | | [기업설명회(IR)개최              ](https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20240905900078){:target="_blank"} |


> **주가 흐름**<a id="price"></a>

![237690](/stock/images/237690.png){: .align-center}


> **주요 가격 변동 지표**<small>[^fn_price_metric]</small>

| **종가** | **전일대비** | **5일** | **20일** | **60일** | **120일** |
| -------: | -----------: | ------: | -------: | -------: | --------: |
| 99,500 | <span style="color: cornflowerblue">-0.8<small>%</small></span> | <span style="color: cornflowerblue">-5.7<small>%</small></span> | <span style="color: tomato">9.2<small>%</small></span> | <span style="color: tomato">7.7<small>%</small></span> | <span style="color: tomato">3.3<small>%</small></span> |
| **1년** | **편차** | **샤프** | **MDD** | **AvDD** | **MARr** |
| <span style="color: tomato">20.3<small>%</small></span> | 59.0<small>%</small> | 0.34 | -32.3<small>%</small> | -14.8<small>%</small> | -0.6 |


> **주요 재무 지표**<small>[^fn_finance_metric]</small>

| **업종**<small>[^fn_sector_abbr]</small> | **PER** | **PBR** | **DIV** | **평가**<small>[^fn_finance_basic_tags]</small> |
| :--------------------------------------- | ------: | ------: | ------: | ----------------------------------------------: |
| Q:제약 | 95.6 | 4.9 | 0.5<small>%</small> | 고PER |



{% include /commons/ads/adsense.html %}

> **세부 재무/투자 정보 제공 사이트**

| [네이버](https://m.stock.naver.com/domestic/stock/237690/finance/summary){:target="_blank"}<sup><small>모바일</small></sup> | [네이버](https://finance.naver.com/item/coinfo.naver?code=237690){:target="_blank"} | [FnGuide](https://comp.fnguide.com/SVO2/ASP/SVD_Invest.asp?gicode=A237690&MenuYn=Y){:target="_blank"} |
| :---: | :---: | :---: |
| [와이즈리포트](https://comp.wisereport.co.kr/company/c1040001.aspx?cmp_cd=237690){:target="_blank"} | [밸류라인](https://www.valueline.co.kr/finance/summary/237690){:target="_blank"} | [한국경제](https://markets.hankyung.com/stock/237690/financial-summary){:target="_blank"} |


> **주요 기술 지표**<small>[^fn_tech_metric]</small>


![237690](/stock/images/237690_tech.png){: .align-center}

| **기술 지표** | **1년** | **편차** | **샤프** | **MDD** | **AvDD** |
| :------------ | ------: | -----------: | -------: | ------: | -------: |
| 거치식 | 20.3<small>%</small> | 59.0<small>%</small> | 0.34 | -32.3<small>%</small> | -14.8<small>%</small> |
| 적립식[^fn_tech_metric_dca] | 28.2<small>%</small> | 58.5<small>%</small> | 0.48 | -34.8<small>%</small> | -10.3<small>%</small> |
| Sig. M[^fn_tech_metric_sigm] | 62.1<small>%</small> | 48.4<small>%</small> | 1.28 | -22.4<small>%</small> | -9.6<small>%</small> |
| SMA<small><sub>(5)</sub></small>[^fn_tech_metric_sma_i] | -26.9<small>%</small> | 47.7<small>%</small> | -0.56 | -36.2<small>%</small> | -21.0<small>%</small> |
| SMA<small><sub>(20)</sub></small>[^fn_tech_metric_sma_i] | 5.8<small>%</small> | 49.2<small>%</small> | 0.12 | -24.5<small>%</small> | -9.7<small>%</small> |
| SMA<small><sub>(60)</sub></small>[^fn_tech_metric_sma_i] | 15.6<small>%</small> | 49.1<small>%</small> | 0.32 | -26.0<small>%</small> | -10.9<small>%</small> |
| SMA<small><sub>(120)</sub></small>[^fn_tech_metric_sma_i] | 32.8<small>%</small> | 50.9<small>%</small> | 0.64 | -23.5<small>%</small> | -7.4<small>%</small> |
| SMA<small><sub>(240)</sub></small>[^fn_tech_metric_sma_i] | 4.8<small>%</small> | 51.0<small>%</small> | 0.09 | -32.3<small>%</small> | -8.0<small>%</small> |
| MACD[^fn_tech_metric_macd] | 8.3<small>%</small> | 47.6<small>%</small> | 0.17 | -30.8<small>%</small> | -11.5<small>%</small> |


> **주가 흐름 유사 종목**<a id="corr"></a><small>[^fn_corr_long]</small>

![237690](/stock/images/237690_corr.png){: .align-center}

|       | [오스코텍](/039200/) | [LS ELECTRIC](/010120/) | [제룡전기](/033100/) |
| :---: | :------------------------------------: | :------------------------------------: | :------------------------------------: |
|       | [삼천당제약](/000250/) | [한화오션](/042660/) | [KB금융](/105560/) |


> **가상 레버리지 상품에 투자했다면**<a id="2x"></a><small>[^fn_lev]</small>

![237690](/stock/images/237690_2x.png){: .align-center}


> **관련 정보**

- [Q:제약 업종 목록](/stats/sector/kosdaq_업종_제약_종목/){: .btn .btn--info} [고PER 목록](/fn/fn_high_per/){: .btn .btn--info}

{% include commons/footnotes.md %}